Literature DB >> 24072749

Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A.

Pawel Mroz1, Fatma Vatansever, Angelika Muchowicz, Michael R Hamblin.   

Abstract

Photodynamic therapy (PDT) involves the intravenous administration of photosensitizers followed by illumination of the tumor with visible light, leading to local production of reactive oxygen species that cause vascular shutdown and tumor cell death. Antitumor immunity is stimulated after PDT because of the acute inflammatory response that involves activation of the innate immune system, leading to stimulation of adaptive immunity. We carried out PDT using benzoporphyrin derivative and 690-nm light after 15 minutes, in DBA/2 mice bearing either the mastocytoma, P815, which expresses the naturally occurring cancer/testis antigen P1A, or the corresponding tumor P1.204 that lacks P1A expression. Tumor cures, significantly higher survival, and rejection of tumor rechallenge were obtained with P815, which were not seen with P1.204 or seen with P815 growing in nude mice. Both CD4 and CD8 T cells had higher levels of intracellular cytokines when isolated from mice receiving PDT of P815 tumors than P1.204 tumors and CD8 T cells from P815-cured mice recognized the peptide epitope of the P1A antigen (LPYLGWLVF) using pentamer staining. Taken together, these findings show that PDT can induce a potent antigen- and epitope-specific immune response against a naturally occurring mouse tumor antigen.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24072749      PMCID: PMC3831658          DOI: 10.1158/0008-5472.CAN-11-2572

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors.

Authors:  Ivana Cecic; Mladen Korbelik
Journal:  Cancer Lett       Date:  2002-09-08       Impact factor: 8.679

Review 3.  Photodynamic therapy for cancer.

Authors:  Dennis E J G J Dolmans; Dai Fukumura; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

4.  Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide.

Authors:  B Lethé; B van den Eynde; A van Pel; G Corradin; T Boon
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

5.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.

Authors:  J L Maryanski; M Marchand; C Uyttenhove; T Boon
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

Review 6.  Cancer testis antigens: a novel target in lung cancer.

Authors:  Maurizio Chiriva-Internati; Apurva Pandey; Radhi Saba; Minji Kim; Charles Saadeh; Tiajani Lukman; Raffaella Chiaramonte; Marjorie Jenkins; Everardo Cobos; Cynthia Jumper; Read Alalawi
Journal:  Int Rev Immunol       Date:  2012-10       Impact factor: 5.311

7.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Authors:  A B Bakker; M W Schreurs; A J de Boer; Y Kawakami; S A Rosenberg; G J Adema; C G Figdor
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

8.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

Authors:  C Uyttenhove; J Maryanski; T Boon
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

9.  The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.

Authors:  B Van den Eynde; B Lethé; A Van Pel; E De Plaen; T Boon
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

10.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  V Brichard; A Van Pel; T Wölfel; C Wölfel; E De Plaen; B Lethé; P Coulie; T Boon
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

View more
  18 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

2.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

Review 3.  Photodynamic Therapy and Immunity: An Update.

Authors:  Riddhi Falk-Mahapatra; Sandra O Gollnick
Journal:  Photochem Photobiol       Date:  2020-04-23       Impact factor: 3.421

Review 4.  Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells.

Authors:  Wojciech Szlasa; Natalia Janicka; Natalia Sauer; Olga Michel; Bernadetta Nowak; Jolanta Saczko; Julita Kulbacka
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

5.  Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model.

Authors:  Hing-Yuen Yeung; Pui-Chi Lo; Dennis K P Ng; Wing-Ping Fong
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

6.  5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.

Authors:  Malgorzata Wachowska; Magdalena Gabrysiak; Angelika Muchowicz; Weronika Bednarek; Joanna Barankiewicz; Tomasz Rygiel; Louis Boon; Pawel Mroz; Michael R Hamblin; Jakub Golab
Journal:  Eur J Cancer       Date:  2014-02-18       Impact factor: 9.162

Review 7.  Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.

Authors:  Demian van Straten; Vida Mashayekhi; Henriette S de Bruijn; Sabrina Oliveira; Dominic J Robinson
Journal:  Cancers (Basel)       Date:  2017-02-18       Impact factor: 6.639

8.  Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer.

Authors:  Victoria M Kim; Xingyi Pan; Kevin C Soares; Nilofer S Azad; Nita Ahuja; Christopher J Gamper; Alex B Blair; Stephen Muth; Ding Ding; Brian H Ladle; Lei Zheng
Journal:  JCI Insight       Date:  2020-05-07

Review 9.  Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity.

Authors:  Malgorzata Wachowska; Angelika Muchowicz; Jakub Golab
Journal:  Front Oncol       Date:  2015-07-30       Impact factor: 6.244

10.  Epigenetic remodeling combined with photodynamic therapy elicits anticancer immune responses.

Authors:  Malgorzata Wachowska; Magdalena Gabrysiak; Jakub Golab
Journal:  Oncoimmunology       Date:  2014-05-15       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.